Advances in Hypertriglyceridemia Treatment

Slides:

Advertisements

Similar presentations

Ronald A. Codario, MD Assistant Clinical Professor of Medicine

Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

CVD risk estimation and prevention: An overview of SIGN 97.

Lipid Disorders and Management in Diabetes

DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279)

Polypill x Aspirin Project Groups 3 and 4

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Drugs Used to Treat Dyslipidemias Chapter 22 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.

DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:

Presented by Slyter Nutrition Consulting Services.

The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.

Blood Pressure and Lipid Trials: Rationale, Importance and Design

The LIVES Sub-analysis

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Drugs for Lipid Disorders

The MASS-DAC Study.

Copyright © 2000 American Medical Association. All rights reserved.

AIM HIGH Niacin plus Statin to prevent vascular events

Copyright © 2012 American Medical Association. All rights reserved.

Cardiovascular System

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Updates and Perspectives in Diabetic Dyslipidemia

What is the likely mechanism by which HDL-C reduces coronary heart disease?

FATS- Familial Atherosclerosis Treatment Study

Statin Selection in the Elderly

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

An Endocrinology Clinic in Dyslipidemia

Omega-3 Prescriptions vs Supplements in Practice

Diabetes and Dyslipidemia

New Insights on PPAR Agonists For Cardiovascular Disease

Back to the Basics of Dyslipidemia

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cholesteryl Ester Transfer Protein Inhibitors

The Chemical Differences Between EPA and DHA.

Select Topics in Cardiovascular Medicine

Case Study: 45-year-old Man

Amarin Beyond LDL: Focused Insights High Triglycerides, Very High Triglycerides and CV Residual Risks December 2017.

Cardiovascular disease

The Chemical Differences Between EPA and DHA.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

An Update on PCSK9 Inhibitors

Cardiovascular disease

Residual Risk After Statin Therapy:

Jun M, et al. Lancet 2010 Epub May 10

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Diabetes and Cardiovascular Disease Risk: The Hard Truth

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Diabetes and Cardiovascular Disease Risk: The Hard Truth

I. Introduction American Journal of Kidney Diseases

Pharmacotherapy for Diabetic Coronary Disease:

Managing Age-Related Clinical Issues in Hemophilia

Préparation ESC Septembre

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Potential mechanisms whereby statins may reduce the risk of stroke

An Update on PCSK9 Inhibitors

Goals & Guidelines A summary of international guidelines for CHD

Addressing Cardiovascular Events:

Pandemic Lipid Edition

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Lipids, the Heart, and the Kidney

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Section 6: Update on lipid treatment guidelines

QRISK 3 – Clare Hawley - Summary slide

Presentation transcript:

Advances in Hypertriglyceridemia Treatment

Meta-analysis of 61 Studies TGs Associated With CVD, All-cause Mortality

TG Levels What Is Considered High?

Managing Hypertriglyceridemia Lifestyle Interventions

Effects of Nutrition Practices on TG Lowering

APOC3 Mutations Reduce Coronary Heart Disease Risk

Post hoc Analysis of AIM-HIGH Niacin ER in Patients With High TG and Low HDL-C Levels

IMPROVE-IT Ezetimibe/Simvastatin Reduces Risk of Cardiovascular Events

Lipid Effects of Drug Classes in Dyslipidemia and Hypertriglyceridemia

Select Omega-3 Outcomes Studies